Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma

American Journal of Health-System Pharmacy

Volumn 67, Issue 10, 2010, Pages 793-797

  Kavanaugh, Shannon A ^a   White, Lisa A ^a   Kolesar, Jill M ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b U of WI School of Pharmacy   (United States)

Author keywords

Anticoagulants; Anticonvulsants; Antineoplastic agents; Dosage; Drug administration; Drug interactions; Excretion; Lymphoma; Mechanism of action; Metabolism; Pharmacokinetics; Toxicity; Valproic acid; Vorinostat; Warfarin

Indexed keywords

BEXAROTENE; CYTOCHROME P450 ISOENZYME; GLUCURONOSYLTRANSFERASE; HISTOCOMPATIBILITY ANTIGEN; VALPROIC ACID; VORINOSTAT; WARFARIN; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ANEMIA; ANTIGEN EXPRESSION; APOPTOSIS; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; HISTOCOMPATIBILITY COMPLEX; HISTONE ACETYLATION; HUMAN; IMMUNE RESPONSE; INTERNATIONAL NORMALIZED RATIO; LARGE CELL LYMPHOMA; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PRIORITY JOURNAL; PROTEINURIA; PROTHROMBIN TIME; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCRIPTION REGULATION; BIOLOGICAL MODEL; CLINICAL TRIAL; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, CUTANEOUS; MODELS, BIOLOGICAL; SKIN NEOPLASMS;

EID: 77956025668     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090247     Document Type: Review

References (28)

1. Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2008; 22:979-96.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
3. De Coninck EC, Kim YH, Varghese A et al. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol. 2001; 19:779-84. (Pubitemid 32119093)
4. Mann BS, Johnson JR, Cohen MH et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247-52. (Pubitemid 350106355)
5. Zolinza (vorinostat) full prescribing information. Whitehouse Station, NJ: Merck & Co.; 2006 Oct.
6. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541-52. (Pubitemid 47255934)
7. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998; 12:599-606. (Pubitemid 28134293)
8. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004; 18:2315-35. (Pubitemid 39310518)
9. Codd R, Braich N, Liu J et al. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Int J Biochem Cell Biol. 2009; 41:736-9.
10. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003; 4:13-8. (Pubitemid 36904157)
11. Kelly WK, O'Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005; 23:3923-31. (Pubitemid 46218695)
12. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet? Pharmacotherapy. 2008; 28:755-68. (Pubitemid 351975379)
13. Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001; 1:65-70. (Pubitemid 33757985)
14. ClinicalTrials.gov. Vorinostat trials. www.clinicaltrials.gov/ct2/ results?term=vorinostat (accessed 2009 May 7).
15. Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109:31-9. (Pubitemid 46053039)
16. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25:3109-15. (Pubitemid 47218059)
17. U.S. Department of Health and Human Services. Common terminology criteria for adverse events, version 4.0. http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev4.pdf (accessed 2009 Jul 7).
18. Vorinostat (Zolinza) for cutaneous T-cell lymphoma. Med Lett Drugs Ther. 2007;49:23-4.
19. Wise LD, Turner KJ, Kerr JS. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res B Dev Reprod Toxicol. 2007; 80:57-68.
20. O'Connor OA, Heaney ML, Schwartz L et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006; 24:166-73. (Pubitemid 46630509)
21. Rubin EH, Agrawal NG, Friedman EJ et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res. 2006; 12:7039-45. (Pubitemid 44974501)
22. Richardson P, Mitsiades C, Colson K et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008; 49:502-7. (Pubitemid 351298334)
23. Garcia-Manero G, Yang H, Bueso-Ramos C et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060-6. (Pubitemid 351213383)
24. Crump M, Coiffier B, Jacobsen ED et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008; 19:964-9. (Pubitemid 351627315)
25. Vansteenkiste J, Van Cutsem E, Dumez H et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2008; 26:483-8.
26. Modesitt SC, Sill M, Hoffman JS et al. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2008; 109:182-6.
27. Woyach JA, Kloos RT, Ringel MD et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodinerefractory thyroid carcinoma. J Clin Endocrinol Metab. 2009; 94:164-70.
28. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA et al. Phase II trial of the histone deacetylase inhibitor vorinostat (zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs. 2008; 26:81-7.